Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


29 June, 2020

Scientific publications

SARS-CoV-2: march toward adaptation


This commentary discusses the evolutionary adaptation of SARS-CoV-2 to its human host. The authors suggest that while the earliest mutations likely did not alter viral fitness , subsequent mutations may have increased the overall mutation rate, generating more diverse viral clades. The emergence of new mutation patterns, coinciding with a decline in fatality rates, suggests a "converged evolution" as the virus adapts. This process may lead to a loss of virulence as SARS-CoV-2 moves toward becoming endemic, allowing it to spread without high mortality.

Benedetti et al., Journal of Medical Virology | 2020